我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

氨氯地平与贝那普利对高血压脑卒中二级预防的效果

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第1期
页码:
34-037
栏目:
临床研究
出版日期:
2014-09-25

文章信息/Info

Title:
Comparison of benazepril and amiodipine in secondary prevention of hypertensive stroke: prospective and randomized trial
作者:
严利南; 曾广民; 王 艾; 刘国韬; 戴国斌
(东莞市南城医院内科，广东 东莞 523000)
Author(s):
YAN Li-nan;  ZENG Guang-min;  WANG Ai;  LIU Guo-tao;  DAI Guo-bin
(Department of Internal Medicine, Nancheng Hospital, Dongguan 523000, Guangdong, China)
关键词:
高血压; 原发性; 脑卒中; 二级预防; 规范治疗; 氨氯地平; 贝那普利
Keywords:
hypertension;  stroke;  secondary prevention;  standard treatment;  amiodipine;  benazepril
分类号:
R743
DOI:
-
文献标识码:
A
摘要:
目的:比较贝那普利与氨氯地平对高血压病并发脑卒中的二级预防效果。方法： 入选常住居民中2个月前因高血压病并发脑卒中的患者325例，在常规治疗、生活干预的基础上，随机、单盲分配到以贝那普利为降压基础治疗的（贝那普利组）178例，以氨氯地平为降压基础治疗的（氨氯地平组）178例，主要观察所有脑卒中的复发率、脑卒中死亡、心肌梗死发生率及总死亡等，观察时间8~72个月，平均46个月。结果： 氨氯地平组的脑卒中复发率显著低于贝那普利组(27.8% vs. 34.0%，P<0.05)，其它心脑血管事件两组相比，差异无统计学意义。结论： 氨氯地平对高血压病并发脑卒中二级预防的效果优于贝那普利。
Abstract:
AIM:To compare the efficacy of benazepril and amiodipine in the secondary prevention of hypertensive stroke. METHODS: Three hundred and fifty-six patients with hypertensive stroke were included in the study. On the basis of routine treatment and life intervention, patients were randomized to receive either benazepril (n=178) or amiodipine (n=178). The rates of stroke recurrence, stroke mortality, myocardial infarction occurrence and death were recorded and compared. Treatment duration was 8-72 months with an average of 46 months. RESULTS: The rate of stroke recurrence after amiodipine treatment was 27.8% (47/178), much lower than 34.0% (53/178) after benazepril treatment (P<0.05). No statistically significant difference was found in other cardiovascular events between groups. CONCLUSION: Amiodipine is significantly more effective than benazepril in the secondary prevention of hypertensive stroke.

参考文献/References

[1]中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组.中国缺血性脑卒中和短暂性脑缺血发作二级预防指南[J].中华神经科杂志,2010,43(2):154-160.
[2]王 薇,赵 冬,孙佳艺,等.中国11省市队列人群危险因素与不同类型心血管病发病危险的比较[J].中华心血管病杂志,2006,34(12):1133-1137.
[3]邝明子,曾广民.我对PROGRESS试验的看法[J].国外医学·脑血管疾病分册,2004,12(8):630-631.
[4]曾广民，黄淑媛，王 艾.脑卒中二级预防中的降压药治疗:钙拮抗剂与血管紧张素转换酶抑制剂,孰优孰劣?[J].中华高血压杂志,2008,16(4):291-293.
[5]中国高血压防治指南修订委员会.中国高血压防治指南(2005年修订版)[M].2005.
[6]饶明俐.中国脑血管病防治指南[J].中风与神经疾病杂志,2006,23(2):132-136.
[7]Schrader J,Lüders S,Kulschewski A,et al.Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention:principal results of a prospective randomized controlled study(Moses)[J].Stroke,2005,36(6):1218-1226.
[8]Wang JG,LI Y,Franklin SS,et al.Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview[J].Hypertension,2007,50(1):181-188.
[9]Rashid P,Leonardi-Bee J,Bath P. Blood pressure reduction and seconaary prevention of stroke and other vascular events[J].Stroke,2003,34(11):2741-2748.
[10]刘国韬曾广民，洪 霞.长效钙拮抗剂-是中国高血压人群降压治疗的最佳选择(09年中国高血压年会大会交流)[J].中国社区医师杂志,2011,13(1):10-11.
[11]王 艾，曾广民.预防脑卒中的降压药物选择分析[J].中西医结合心脑血管病杂志,2005,3(6):494-496.
[12]曾广民，蔡云峰.从价效医学评价抗高血压药物的选择[J].医学临床研究,2002,19(10):321-324.
[13]Verdecchia P1,Reboldi G,Angeli F,et al.Angiotensin-Converting enzyme inhibitors and Calcium Channel blockers for coronary heart disease and stroke prevention[J].Hypertension,2005,46(2):386-392.
[14]中华内科杂志编辑部.钙通道阻滞剂防治脑血管病的中国专家共识[J].中华内科杂志,2006,45(3):261-262.
[15]Webb AJ,Fischer U,Mehta Z,et al.Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis[J].Lancet,2010,375(9718):906-915.
[16]王 文,成云芳,刘力生.中国北京上海广州门诊高血压患者脑卒中风险评估[J].中华高血压杂志,2007,15(z1):14-20.

备注/Memo

备注/Memo:
收稿日期：2014-03-06.
通讯作者：曾广民，主任医师，主要从事血管病内科疾病和高血压病研究Email：zgmych@163.com
作者简介：严利南，主治医师Email：1404919806@qq.com
更新日期/Last Update: 2015-01-20